HC Wainwright & Co. Maintains Buy on Neumora Therapeutics, Lowers Price Target to $7
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $18 to $7.
HC Wainwright & Co. analyst Douglas Tsao maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $18 to $7.